111 related articles for article (PubMed ID: 23052406)
1. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
2. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
[TBL] [Abstract][Full Text] [Related]
3. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.
Shinohara Y; Takahashi N; Nishiwaki K; Hino M; Kashimura M; Wakita H; Hatano Y; Hirasawa A; Nakagawa Y; Itoh K; Masuoka H; Aotsuka N; Matsuura Y; Takahara S; Sano K; Kuroki J; Hata T; Nakamae H; Mugitani A; Nakane T; Miyazaki Y; Niioka T; Miura M; Sawada K
Haematologica; 2013 Sep; 98(9):1407-13. PubMed ID: 23716542
[TBL] [Abstract][Full Text] [Related]
4. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Hijiya N; Maschan A; Rizzari C; Shimada H; Dufour C; Goto H; Kang HJ; Guinipero T; Karakas Z; Bautista F; Ducassou S; Yoo KH; Zwaan CM; Millot F; Patterson BC; Samis J; Izquierdo M; Titorenko K; Li S; Sosothikul D
Blood Adv; 2023 Dec; 7(23):7279-7289. PubMed ID: 37738125
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.
Kuo CY; Wang PN; Hwang WL; Tzeng CH; Bai LY; Tang JL; Chang MC; Lin SF; Chen TY; Chen YC; Tan TD; Hsieh CY; Lin C; Lai C; Miljkovic D; Chang CS
Ther Adv Hematol; 2018 Mar; 9(3):65-78. PubMed ID: 29531660
[TBL] [Abstract][Full Text] [Related]
6. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Sasaki K; Lahoti A; Jabbour E; Jain P; Pierce S; Borthakur G; Daver N; Kadia T; Pemmaraju N; Ferrajoli A; O'Brien S; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):152-62. PubMed ID: 26796981
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Hughes TP; Munhoz E; Aurelio Salvino M; Ong TC; Elhaddad A; Shortt J; Quach H; Pavlovsky C; Louw VJ; Shih LY; Turkina AG; Meillon L; Jin Y; Acharya S; Dalal D; Lipton JH
Br J Haematol; 2017 Oct; 179(2):219-228. PubMed ID: 28699641
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation.
Liu XI; Leong R; Burckart GJ; Dallmann A
J Clin Pharmacol; 2024 Mar; 64(3):323-333. PubMed ID: 37909674
[TBL] [Abstract][Full Text] [Related]
9. Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront.
Al-Dubai HN; Yassin MA; Abdulla MA; Aldapt MS; Ghassoub RS
Case Rep Oncol; 2020; 13(2):664-667. PubMed ID: 32774253
[TBL] [Abstract][Full Text] [Related]
10. A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.
Galimberti S; Abruzzese E; Luci G; Baratè C; Luciano L; Iurlo A; Caocci G; Morganti R; Stefanelli F; Di Paolo A
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543276
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Shah NP; Guilhot F; Cortes JE; Schiffer CA; le Coutre P; Brümmendorf TH; Kantarjian HM; Hochhaus A; Rousselot P; Mohamed H; Healey D; Cunningham M; Saglio G
Blood; 2014 Apr; 123(15):2317-24. PubMed ID: 24569263
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.
Wang X; Roy A; Hochhaus A; Kantarjian HM; Chen TT; Shah NP
Clin Pharmacol; 2013; 5():85-97. PubMed ID: 23788844
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
14. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H; Stenke L; Söderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Höglund M; Koskenvesa P; Lotfi K; Majeed W; Markevärn B; Ohm L; Olsson-Strömberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J;
Eur J Haematol; 2015 Mar; 94(3):243-50. PubMed ID: 25082346
[TBL] [Abstract][Full Text] [Related]
16. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
Boons CC; Swart EL; Timmers L; van de Ven PM; Janssen JJ; Hugtenburg JG
BMC Cancer; 2014 Apr; 14():247. PubMed ID: 24712728
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
[TBL] [Abstract][Full Text] [Related]
18. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.
Tian X; Zhang H; Heimbach T; He H; Buchbinder A; Aghoghovbia M; Hourcade-Potelleret F
J Clin Pharmacol; 2018 Dec; 58(12):1533-1540. PubMed ID: 30179260
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
